Business
Response to Share Price Movement
Response to Share Price Movement.
About this update from Immupharma Plc
28 January 2025 ImmuPharma PLC ("ImmuPharma" or the "Company") Response to Share Price Movement ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, notes the recent movements in its share price. As announced on 9 January 2025, the Company has made innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company's R&D subsidiary ImmuPharma Biotech, has yielded data that provides novel insights into autoimmune disease mechanisms. Through this research, the Company is making a significant step towards personalised medicine in SLE and other autoimmune diseases. (Link: https://www.immupharma.co.uk/news/ ) The ImmuPharma team also attended the JP Morgan and Biotech Showcase healthcare conferences earlier this month. Attending both meetings gave the ImmuPharma team the opportunity to continue positive discussions with a number of global BioPharma companies, that have already expressed an interest in P140 and its unique approach to treating autoimmune diseases. ImmuPharma is not aware of any further material commercial or operational reason for the significant share price movements, however, the Company will continue to update the market on developments, both commercially and scientifically, when appropriate, over the next period. End For further information please contact: ImmuPharma PLC ( www.immupharma.co.uk ) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations +44 (0) 207 206 2650 + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson +44 (0) 203 36 8 3550 +44 (0) 20 3650 3650 +44 (0) 1483 413500 Notes to Editors About ImmuPharma PLC ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases. For additional information about ImmuPharma please visit www.immupharma.co.uk ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.